RxDoctor Payments Data

Hamza Hashmi, MD

Hematology · Charleston, SCNPI 1164862652

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $163,126 of the $244,286 with a category attached, or 66.8%. 41 manufacturers reported payments, led by Karyopharm Therapeutics Inc. at 33.4% of the total. Reporting peaked in 2023 at $122,664 and has fallen 85.8% since, to $17,452 in 2025.

$244,286in general payments, 2019–2025

Across 365 payments — averaging $669.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Karyopharm Therapeutics Inc.$82K
  • Johnson & Johnson$54K
  • GSK$50K
  • Amgen$16K
  • Pfizer$9K
  • Sanofi-aventis U.S. LLC$7K
  • plus $27K from 35 others
$449,678in research payments, 2019–2025

Across 23 payments — averaging $19,551 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$393K
  • Bristol Myers Squibb$28K
  • Takeda Pharmaceuticals U.S.A., Inc.$28K

What the payments were for

  • Consulting fees$36,44315%
  • Speaking & faculty fees$163,12667%
  • Travel & lodging$27,93211%
  • Food & beverage$16,4967%
  • Education$2890%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$87,070
Medicare patients
225
Services billed
581

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide23$340,029
RevlimidLenalidomide17$322,302
EliquisApixaban25$23,247
XareltoRivaroxaban15$18,795
Acyclovir224$3,172
Pantoprazole Sodium70$780
Dexamethasone56$585
Ondansetron OdtOndansetron11$485
Oxycodone Hcl11$157
Montelukast Sodium39$134
Ondansetron Hcl11$75
Gabapentin20$55
Famotidine11$49
Amlodipine Besylate11$33
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim15$22

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$2,258$322,30217 claims
PfizerEliquis$9,346$23,24725 claims
Johnson & JohnsonXarelto$54,350$18,79515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in South Carolinaon file to place this against a meaningful peer group, so we don't.

Other hematology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →